(Q28371031)

English

PIK3CA E545K

genetic variant

GLU545LYS
E545K
RS104886003

In more languages

Statements

missense mutation

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

human chromosome 3

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

178936091

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

178936091

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

positive therapeutic predictor for

medical condition treated

determination method

CIViC evidence level C

CIViC 1-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1550

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

pictilisib / cisplatin combination therapy

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

cervix carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2984

Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2034

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models

determination method

CIViC evidence level D

CIViC 4-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2062

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models

negative therapeutic predictor for

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

adenocarcinoma of the lung

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1171

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/387

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/387

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

colorectal cancer

statement disputed by

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2037

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

colorectal cancer

statement disputed by

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2037

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/3722

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

ado-trastuzumab emtansine

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

Her2-receptor positive breast cancer

statement disputed by

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2036

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

colorectal cancer

statement disputed by

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2217

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Trastuzumab / Lapatinib combination therapy

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/6211

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

adenocarcinoma of the lung

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1670

Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

adenocarcinoma of the lung

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1670

Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

cervix uterine cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2985

Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells

negative prognostic predictor for

determination method

CIViC evidence level B

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2106

PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

dbSNP Reference SNP number

1 reference

HGVS nomenclature

NM_006218.3:c.1633G>A

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

NP_006209.2:p.Glu545Lys

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

ENST00000263967.3:c.1633G>A

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

NC_000003.11:g.178936091G>A

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/104

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28371031&oldid=2014798369"